Daniel Gruskin - 19 May 2021 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Jonathan Quick, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 May 2021
Net transactions value
$0
Form type
4
Filing time
20 May 2021, 20:36:14 UTC
Next filing
10 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Employee Stock Option (Right to buy) Award $0 +60,000 $0.000000 60,000 19 May 2021 Common Stock 60,000 $4.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.